Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

ALKEM is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 2.553000
forwardPE 23.006212
debtToEquity 14.267000
earningsGrowth -0.227000
revenueGrowth 0.146000
grossMargins 0.653840
operatingMargins 0.114240
trailingEps 192.380000
forwardEps 227.721100

With a current ratio of 2.553, ALKEM has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that ALKEM is in a strong position to meet its immediate financial obligations without difficulty.
ALKEM's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
ALKEM's low Debt-to-Equity ratio shows the company avoids heavy reliance on debt. This balanced approach reduces financial risk, as it maintains a healthy equity position without excessive leverage, providing greater financial stability and flexibility.
Alkem Laboratories Limited's low growth in both earnings and revenue indicates a likely decrease in profits. This suggests the company may be facing financial challenges, and investors should be cautious about its future performance.
Alkem Laboratories Limited's negative gross and operating margins suggest that the company is currently facing financial difficulties, as it is unable to cover production and operational costs. This could result in significant losses if not addressed.
ALKEM's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that ALKEM is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

ALKEM's price has consistently hovered around the lower limit of price projections. This pattern suggests that the stock may be underperforming relative to expectations, which could lead to concerns among investors.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


ALKEM has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view ALKEM as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.